123 related articles for article (PubMed ID: 1347417)
21. c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue.
McCann A; Johnston PA; Dervan PA; Gullick WJ; Carney DN
Ir J Med Sci; 1989 Jun; 158(6):137-40. PubMed ID: 2570047
[TBL] [Abstract][Full Text] [Related]
22. [Incidence of amplification of the C-erb B2/Her-2/neu gene in human breast cancer].
Sellami M; Gamoudi M; Krichen K; Kharrat A; Ben Romdhane K; Maalej M
Arch Inst Pasteur Tunis; 1991; 68(1-2):33-41. PubMed ID: 1687309
[TBL] [Abstract][Full Text] [Related]
23. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma.
Soini Y; Mannermaa A; Winqvist R; Kamel D; Poikonen K; Kiviniemi H; Pääkkö P
J Histochem Cytochem; 1994 Jun; 42(6):795-803. PubMed ID: 7910618
[TBL] [Abstract][Full Text] [Related]
24. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
[TBL] [Abstract][Full Text] [Related]
25. C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms.
Vlasoff DM; Baschinsky DY; De Young BR; Morrison CD; Nuovo GJ; Frankel WL
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):237-41. PubMed ID: 12373150
[TBL] [Abstract][Full Text] [Related]
26. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.
Nakajima M; Sawada H; Yamada Y; Watanabe A; Tatsumi M; Yamashita J; Matsuda M; Sakaguchi T; Hirao T; Nakano H
Cancer; 1999 May; 85(9):1894-902. PubMed ID: 10223227
[TBL] [Abstract][Full Text] [Related]
28. [Oncogene organization and expression in breast cancer exemplified by proto-oncogene c-erb B2].
Friedrichs K; Jonat W; Meybohm J; Singh S
Arch Gynecol Obstet; 1989; 245(1-4):658-60. PubMed ID: 2572202
[No Abstract] [Full Text] [Related]
29. [Amplification and expression of oncogenes in human malignant tumors--organ or tissue specificity and prognosis].
Ueda M; Shimizu N; Abe O
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1579-81. PubMed ID: 2573817
[TBL] [Abstract][Full Text] [Related]
30. A subgroup of patients with chronic pancreatitis overexpress the c-erb B-2 protooncogene.
Friess H; Yamanaka Y; Büchler M; Hammer K; Kobrin MS; Beger HG; Korc M
Ann Surg; 1994 Aug; 220(2):183-92. PubMed ID: 7519839
[TBL] [Abstract][Full Text] [Related]
31. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder.
Wood DP; Wartinger DD; Reuter V; Cordon-Cardo C; Fair WR; Chaganti RS
J Urol; 1991 Nov; 146(5):1398-401. PubMed ID: 1942310
[TBL] [Abstract][Full Text] [Related]
32. Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study.
Bandyopadhyay D; Redkar A; Bharde S; Dani H; Sampat M; Mittra I
Acta Oncol; 1994; 33(5):493-8. PubMed ID: 7917361
[TBL] [Abstract][Full Text] [Related]
33. C-erbB-2-oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters.
Tanner B; Friedberg T; Mitze M; Beck T; Oesch F; Knapstein PG
Gynecol Oncol; 1992 Nov; 47(2):228-33. PubMed ID: 1361480
[TBL] [Abstract][Full Text] [Related]
34. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
Bellacosa A; de Feo D; Godwin AK; Bell DW; Cheng JQ; Altomare DA; Wan M; Dubeau L; Scambia G; Masciullo V; Ferrandina G; Benedetti Panici P; Mancuso S; Neri G; Testa JR
Int J Cancer; 1995 Aug; 64(4):280-5. PubMed ID: 7657393
[TBL] [Abstract][Full Text] [Related]
35. Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression.
Shiga K; Shiga C; Sasano H; Miyazaki S; Yamamoto T; Yamamoto M; Hayashi N; Nishihira T; Mori S
Anticancer Res; 1993; 13(5A):1293-301. PubMed ID: 7902061
[TBL] [Abstract][Full Text] [Related]
36. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.
Horak E; Smith K; Bromley L; LeJeune S; Greenall M; Lane D; Harris AL
Oncogene; 1991 Dec; 6(12):2277-84. PubMed ID: 1685017
[TBL] [Abstract][Full Text] [Related]
37. Lack of C-erbB-2 protein expression in pulmonary carcinoid tumours.
Wilkinson N; Hasleton PS; Wilkes S; Quigley A
J Clin Pathol; 1991 Apr; 44(4):343. PubMed ID: 1674253
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
[TBL] [Abstract][Full Text] [Related]
39. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
40. Elevated c-myc messenger RNA in multiple myeloma cell lines.
Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L
Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
